Astellas Pharma GmbH
Astellas Pharma Inc. is dedicated to improving global health through innovative and reliable pharmaceutical products. The company focuses on therapeutic areas such as Urology, Oncology, Immunology, Nephrology, and Neuroscience, while also advancing new therapeutic areas and discovery research leveraging new technologies. Astellas aims to turn innovative science into value for patients and is at the forefront of healthcare change.
Industries
Nr. of Employees
Very Large (1000+)
Astellas Pharma GmbH
Patents
Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
US-12202908-B2
View Details
Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
US-12202908-B2
View DetailsProducts
Androgen receptor inhibitor (enzalutamide)
Oral androgen receptor signaling inhibitor developed for castration-resistant prostate cancer, evaluated across multiple randomized Phase 3 programs and supportive clinical studies.
Antibody-drug conjugate targeting Nectin-4
ADC composed of a monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting payload, under clinical investigation as monotherapy and in combination with immune checkpoint inhibitors for urothelial cancer.
HIF prolyl hydroxylase inhibitor (roxadustat)
Orally administered small-molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 development for treatment of anemia associated with chronic kidney disease, evaluated in dialysis and non‑dialysis populations.
FLT3 inhibitor (gilteritinib)
Small-molecule inhibitor with activity against FLT3-ITD and FLT3‑TKD mutations developed for acute myeloid leukemia; evaluated in Phase 1 dose‑escalation/expansion studies including combinations with intensive chemotherapy.
Bispecific CD19‑directed CD3 T‑cell engager
Bispecific antibody construct that engages CD19 on B‑lineage tumor cells and CD3 on T cells to mediate targeted cytotoxicity; submitted for regulatory review for relapsed or refractory B‑cell precursor acute lymphoblastic leukemia.
Selective SGLT2 inhibitor (ipragliflozin)
Selective SGLT2 inhibitor developed for glycemic control by inhibiting renal glucose reuptake; under supplemental indication filings for type 1 diabetes and marketed formulations for type 2 diabetes.
Androgen receptor inhibitor (enzalutamide)
Oral androgen receptor signaling inhibitor developed for castration-resistant prostate cancer, evaluated across multiple randomized Phase 3 programs and supportive clinical studies.
Antibody-drug conjugate targeting Nectin-4
ADC composed of a monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting payload, under clinical investigation as monotherapy and in combination with immune checkpoint inhibitors for urothelial cancer.
HIF prolyl hydroxylase inhibitor (roxadustat)
Orally administered small-molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 development for treatment of anemia associated with chronic kidney disease, evaluated in dialysis and non‑dialysis populations.
FLT3 inhibitor (gilteritinib)
Small-molecule inhibitor with activity against FLT3-ITD and FLT3‑TKD mutations developed for acute myeloid leukemia; evaluated in Phase 1 dose‑escalation/expansion studies including combinations with intensive chemotherapy.
Bispecific CD19‑directed CD3 T‑cell engager
Bispecific antibody construct that engages CD19 on B‑lineage tumor cells and CD3 on T cells to mediate targeted cytotoxicity; submitted for regulatory review for relapsed or refractory B‑cell precursor acute lymphoblastic leukemia.
Selective SGLT2 inhibitor (ipragliflozin)
Selective SGLT2 inhibitor developed for glycemic control by inhibiting renal glucose reuptake; under supplemental indication filings for type 1 diabetes and marketed formulations for type 2 diabetes.
Services
Conducts collaborative screening of proprietary compound libraries and joint research programs with public-private partnerships and academic partners to discover leads for infectious diseases and other indications.
Provides co-development, co-promotion and co-commercialization services including joint marketing and information provision to medical institutions under formal agreements.
Sponsors and manages multi-center clinical trials across phases I–III, including safety/tolerability assessments, dose finding, expansion cohorts and endpoint-driven randomized trials.
Manages transfer of marketed-product assets, supplies of active pharmaceutical ingredients and supply continuity planning during portfolio reorganizations or asset transfers.
Develops production and formulation conditions for plant-based oral vaccine platforms, including evaluation of cultivation and processing methods to enable practical manufacture and storage.
Prepares and files marketing authorization applications and supplemental indications; manages regulatory interactions to secure designations and approvals across territories.
Conducts collaborative screening of proprietary compound libraries and joint research programs with public-private partnerships and academic partners to discover leads for infectious diseases and other indications.
Provides co-development, co-promotion and co-commercialization services including joint marketing and information provision to medical institutions under formal agreements.
Sponsors and manages multi-center clinical trials across phases I–III, including safety/tolerability assessments, dose finding, expansion cohorts and endpoint-driven randomized trials.
Manages transfer of marketed-product assets, supplies of active pharmaceutical ingredients and supply continuity planning during portfolio reorganizations or asset transfers.
Develops production and formulation conditions for plant-based oral vaccine platforms, including evaluation of cultivation and processing methods to enable practical manufacture and storage.
Prepares and files marketing authorization applications and supplemental indications; manages regulatory interactions to secure designations and approvals across territories.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Cell therapy and regenerative medicine
- Antibody-based therapeutics development
Key Technologies
- Antibody-drug conjugates (ADC)
- Bispecific T-cell engager constructs
- Allogeneic cell therapy using engineered pluripotent stem cells
- Viral vector-mediated gene editing
News & Updates
Positive efficacy results from a Phase 3 trial for Roxadustat in chronic kidney disease patients with anemia.
Agreement to extend the sales and co-promotion of Telmisartan in Japan until March 31, 2020.
Collaboration to screen compounds for potential new antimalarial drugs, funded by GHIT Fund.
Astellas and Universal Cells enter into an agreement to develop cell therapies that can be administered without HLA matching.
Initial safety and efficacy data from a Phase 1 trial of Gilteritinib in newly diagnosed AML patients.
Financial results show a slight decrease in sales and profit, with growth in key products like XTANDI.
Positive efficacy results from a Phase 3 trial for Roxadustat in chronic kidney disease patients with anemia.
Agreement to extend the sales and co-promotion of Telmisartan in Japan until March 31, 2020.
Collaboration to screen compounds for potential new antimalarial drugs, funded by GHIT Fund.
Astellas and Universal Cells enter into an agreement to develop cell therapies that can be administered without HLA matching.
Initial safety and efficacy data from a Phase 1 trial of Gilteritinib in newly diagnosed AML patients.
Financial results show a slight decrease in sales and profit, with growth in key products like XTANDI.